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Background: Type 2 diabetes mellitus is increasing dramatically in sub-Saharan Africa, and genetic predisposition is
likely involved in that. Yet, genetic variants known to confer increased susceptibility among Caucasians are far from
being established in African populations. In Ghanaian adults, we examined associations of several of these
polymorphisms with type 2 diabetes.
Methods: A hospital-based case–control study on type 2 diabetes (and hypertension) was conducted in Kumasi,
Ghana. TCF7L2 rs7903146, KCNJ11 rs5219, PPARγ rs1801282 and CAPN10 rs3842570, rs3792267, and rs5030952 were
typed and associations with type 2 diabetes and phenotypic traits examined.
Results: 675 patients with type 2 diabetes and 377 controls were compared. The minor allele frequency of the
TCF7L2 (T) allele was 0.33. In the multivariate model, this allele increased the risk of type 2 diabetes by 39% (95%
confidence interval (CI), 1.07-1.81; p = 0.014). The minor alleles KCNJ11 (G) and PPARγ (G) were practically absent
(each, 0.001). Minor allele frequencies of CAPN10 were for −43 (A) 0.11 and for −63 (C) 0.46. These variants showed
no significant associations with type 2 diabetes. Two CAPN10 haplotypes tended to protect against type 2 diabetes:
211 (aOR, 0.32; 95% CI, 0.03-1.92; p = 0.31) and 221 (aOR, 0.73; 95% CI, 0.48-1.10; p = 0.13).
Conclusions: In urban Ghana, the frequency of the TCF7L2 rs7903146 (T) allele is comparable to the one in
Caucasians; the association with type 2 diabetes is slightly weaker. The risk allele KCNJ11 (G) and the protective
allele PPARγ (G) are virtually absent. The potential influence of comparatively rare CAPN10 haplotypes on type 2
diabetes risk in this population requires further evaluation. Large-scale genetic studies among native Africans
aiming at fine-mapping the candidate genes are needed to identify the actual factors involved in their increased
susceptibility to type 2 diabetes.
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In low-income countries, infectious diseases and malnu-
trition continue to be the predominant causes of mor-
bidity and mortality [1]. At the same time, these regions
are facing an enormous growth of chronic non-
communicable diseases, notably type 2 diabetes mellitus.
In sub-Saharan Africa (SSA) alone, the number of* Correspondence: ina.danquah@dife.de
1Institute of Tropical Medicine and International Health, Charité,
Universitätsmedizin Berlin, Spandauer Damm 130, 14050 Berlin, Germany
2Department of Molecular Epidemiology, German Institute of Human
Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558
Nuthetal, Germany
Full list of author information is available at the end of the article
© 2013 Danquah et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordiabetic patients is projected to double from 15 to 28
million within the next decade [2]. The actual reasons
for this development are unclear. Only 3% of published
data on type 2 diabetes originate from African popula-
tions, mainly black Americans. Overall, Africans are
affected earlier by type 2 diabetes and with more severe
complications than their Caucasian counterparts. De-
layed diagnosis and poor management due to a low
socio-economic status (SES) are among the causes.
However, differences between blacks and whites in the
prevalence and severity of type 2 diabetes do persist
even when demographic, socio-economic, behavioral,
and clinical parameters are taken into account [3]. Thisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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susceptibility of Africans towards this classic polygenic
disease [4].
More than 60 susceptibility variants for type 2 diabetes
have been identified, and their number increases con-
tinuously [5,6]. Among native Africans, the meaning of
these polymorphisms for type 2 diabetes is far from
being understood. Here, we examined in a Ghanaian
population three elsewhere well-established and repro-
ducibly associated type 2 diabetes variants, namely poly-
morphisms of transcription factor 7-like 2 (TCF7L2),
potassium inwardly-rectifying channel J11 (KCNJ11),
and peroxisome proliferator-activated receptor γ (PPARγ)
(reviewed by [7]). TCF7L2 is involved in insulin secre-
tion, and the TCF7L2 rs7903146 single nucleotide poly-
morphism (SNP) constitutes the best established risk
allele in Caucasian populations conferring an overall
relative risk for type 2 diabetes of 1.44 [6,8]. The SNP
has recently been reported to be strongly associated with
type 2 diabetes also in African Americans (adjusted odds
ratio (OR), 1.37) [8]. Notably, in native Africans, the role
of TCF7L2 rs7903146 has been examined only once,
however, in an ethnically mixed population of Ghanaians
and Nigerians, yielding an OR of 1.45 [9].
Two further classic type 2 diabetes risk alleles, KCNJ11
rs5219 (G) (influencing insulin secretion) and PPARγ
rs1801282 (C) (influencing insulin sensitivity) are con-
sidered to be very rare and very frequent, respectively, in
individuals of African descent [8,10-12]. Irrespective of
the consequently limited power of detecting associations
with type 2 diabetes, we aimed at confirming their fre-
quencies in a native West African population.
Lastly, we examined CAPN10 variants (rs3792267
(−43), rs3842570 (−19), and rs5030952 (−63) [4]) of the
Ca2+-dependent cysteine protease calpain 10 which may
influence both, insulin secretion and peripheral sensitiv-
ity. In the only study among native West Africans,
CAPN10 polymorphisms and type 2 diabetes were not
associated, even though the potential risk allele −43 (A)
was more frequent among patients with type 2 diabetes
[13]. Notably, -43 (G) is considered the type 2 diabetes
risk allele in some studies [4], while it confers improved
insulin secretion in others [14,15].
The aim of the present study was therefore to examine
the allele frequencies of selected genetic polymorphisms,
common and replicated in other populations, among
urban Ghanaians as well as the associations with type 2
diabetes and phenotypic traits.
Methods
Study site and design
The study was conducted from August 2007 through
June 2008 at Komfo Anokye Teaching Hospital (KATH),
Kumasi, Ghana. Detailed descriptions of the study siteand the recruitment procedures are presented elsewhere
[16]. In brief, about 6% of the adult population in this
region exhibit type 2 diabetes, 29% have hypertension,
and roughly 23% are overweight [17-19]. The diabetes
center and the hypertension clinic at the hospital each
deliver health care to >100 patients per week, the
majority of whom are urban residents living on small-
scale trading. The unmatched case–control study was
designed to primarily identify factors associated with
type 2 diabetes. The present analysis aims at genetic as-
sociations with type 2 diabetes and with diabetic traits
among the control group.
The study protocol was reviewed and approved by the
Ethics Committee, School of Medical Sciences, Univer-
sity of Science and Technology, Kumasi, and informed
written consent was obtained from all participants.
Recruitment procedures and examinations
After providing detailed information on the objectives
and procedures of the study, patients were recruited
from the diabetes center (n = 495) and the hypertension
clinic (n = 451). Patients encouraged members of their
community (n = 222) to participate in the study as pre-
liminary controls. Likewise, further preliminary controls
were recruited among outpatients (n = 150) and hospital
staff (n = 148). After exclusion of type 2 diabetes and
hypertension (see below), they were included into the
study as controls.
All participants were instructed on fasting, abstaining
from cigarette smoking, alcohol and coffee consumption
as well as on avoiding excessive physical activity begin-
ning at 10:00 p.m. the day before examination. On the
day of examination, each participant underwent a meas-
urement of fasting plasma glucose (FPG). The socio-
demographic data were documented; the participants
were physically examined and interviewed with respect
to residence, own and family history of diabetes and
hypertension, medications, smoking behavior and educa-
tion. Venous blood and urine samples were collected.
Weight, height, waist and hip circumferences were mea-
sured (all devices Seca, Germany). After 10 minutes rest-
ing time in an air-conditioned examination room, blood
pressure and heart rate were assessed at 0, 5, and
10 min. (M8 Comfort, Omron, Japan).
Laboratory analyses
FPG (fluoride whole blood, tubes cooled at +4°C) and
urinary albumin were measured photometrically (Glu-
cose 201+ & Albumin Systems; HemoCue, Ångelholm,
Sweden). Glucose concentration is presented as plasma
equivalents. The coefficients of variation ranged between
1.7-6.1% and 4.9-8.0%, respectively.
DNA was extracted from stabilized full blood aliquots
(stabilizing buffer AS1 and QIAamp DNA blood mini
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rs5219 and PPARγ rs1801282 were genotyped by the
LightCycler 480 device (Roche Diagnostics, Mannheim,
Germany) using commercially available primers and
probes (TIB MOLBIOL, Berlin, Germany) (Additional
file 1: Table S1). CAPN10 rs3792267 was detected by a
mutagenically separated PCR method, which uses a
common forward primer and two allele-specific reverse
primers. As for CAPN10 rs3842570, this insertion/dele-
tion polymorphism was amplified by forward and reverse
primers, whereas CAPN10 rs5030952 was identified as
restriction fragment length polymorphism [21]. For each
batch of genotyping assay, positive controls of known se-
quence were included and the evaluation of results was
done manually as well as per individual sample. When-
ever an assay was negative, unclear or implausible, it was
repeated.
Power analysis
For the most prominent candidate variant of type 2 dia-
betes susceptibility, i.e., TCF7L2 rs7903146, we assumed
an additive effect, yielding an OR of at least 1.35 [9]. At
an allele frequency of 0.30, given a significance level of
α = 0.05 and a 95% confidence interval (CI), the present
sample size of 1052 (2 cases vs. 1 control) is sufficient to
replicate this OR with a probability (power) of 84%.
Given minor allele frequencies (MAFs) of 0.11, 0.23 and
0.46 for CAPN10 –43, –19 and −63 at an expected dia-
betes prevalence of 6%, an OR of 1.30 can be detected at
the given sample size (675 cases and 377 controls) with
a power of 66%, 67% and 79%, respectively. Power calcu-
lations have been performed using Quanto 1.2.4 [22].
Data management and analyses
Body mass index (BMI) was calculated as weight in kg
divided by height squared in m. Overweight and obesity
were defined as BMI ≥25.0-29.9 kg/m2 and ≥30.0 kg/m2,
respectively. Central adiposity was defined as waist cir-
cumference ≥102 cm (male) and ≥88 cm (female). Type
2 diabetes was defined as FPG ≥7 mmol/l and/or
documented anti-diabetic medication. Hypertension de-
noted a mean of blood pressure ≥140/90 mmHg of three
independent measurements and/or documented anti-
hypertensive treatment. Controls were negative for both
conditions. Microalbuminuria was defined as ≥20 mg/l.
Distributions of categorical and continuous parameters
were compared between diabetic patients and controls
by χ2-test and Mann–Whitney-U-test, respectively. ORs
for type 2 diabetes, 95% CI and p values were calculated
by logistic regression analyses. CAPN10 haplotypes were
reconstructed from genotype data using the software
package PHASE version 2.1 [23,24]. With respect to
genetic polymorphisms, we assumed an additive effect of
candidate alleles on type 2 diabetes risk (homozygousfor non-risk allele, 0; heterozygous for risk allele, 1;
homozygous for risk allele, 2). The crude odds ratio
(OR) and a multivariate estimate adjusted for age, gen-
der, BMI ≥25.0 kg/m2 and hypertension status were cal-
culated. In a second analysis, associations of SNPs with
phenotypic traits among the controls were calculated
using linear regression models. These traits were waist
circumference, BMI, FPG, systolic and diastolic blood
pressure, and urinary albumin. Non-normally distributed
parameters were loge transformed.
Results
Study population
Overall, we recruited 1466 study participants, of whom
46% (675) presented with type 2 diabetes and 26% (377)
were controls; further 414 (28%) had hypertension only
and were not regarded for the present analysis. The de-
tailed description of the study population including
demographic characteristics, clinical and anthropometric
data, medical history, physical activity, nutritional behav-
ior and socioeconomic background is presented else-
where [16].
The majority of patients with type 2 diabetes (97%)
regularly attended the diabetes center, presenting with a
median duration of type 2 diabetes of 5.0 (interquartile
range, 2.0-9.0) years. Characteristics of patients and con-
trols are presented in Table 1. The participants were
mainly female, middle-aged, overweight and of low SES.
As compared to controls, diabetic patients were signifi-
cantly older (p < 0.001), more often centrally adipose
(69% vs. 53%; p < 0.001) and had the lowest SES
(unemployment, 37% vs. 10%, p < 0.001). Hypertension
(63%) and microalbuminuria (43%) were frequent among
diabetic patients. Also, they more often reported a family
history of diabetes and hypertension than controls (each
p < 0.001). Metformin-based therapies (78%) and combi-
nations with sulfonylureas (61%) were predominating
[16]. Except for increased rates of smoking among type
2 diabetes cases, no further differences were observed
compared to controls. Self-reported Akan ethnicity was
88% in the type 2 diabetes group and 84% among con-
trols (p = 0.11).
Genetic variants and type 2 diabetes
Genotyping success was 97.1% for PPARγ rs1801282,
99.6% for each variant of CAPN10 (rs3842570, rs3792267,
rs5030952), 99.7% for TCF7L2 rs7903146 and 100% for
KCNJ11 rs5219. All genotypes obeyed the Hardy-
Weinberg equilibrium. Minor allele frequencies and asso-
ciations with type 2 diabetes are presented in Table 2.
The TCF7L2 (T) allele was increased in the type 2
diabetes group (0.36) compared to the controls (0.30;
p = 0.01). In multivariate analysis adjusting for age, gen-
der, BMI ≥25.0 kg/m2 and hypertension status, TCF7L2
Table 1 Characteristics of 1052 urban Ghanaians
Characteristics Controls Type 2 diabetes P
N 377 675
Age (years) 38.8 ± 14.8 54.7 ± 13.4 <0.001
Sex (female) 76.4 (288) 74.7 (504) 0.50
Residence (Kumasi metropolitan area) 79.3 (299) 70.8 (476) 0.003
Ethnic group (Akan) 84.4 (318) 87.7 (592) 0.11
Systolic blood pressure (mmHg) 116.0 ± 11.3 138.3 ± 23.9 <0.001
Diastolic blood pressure (mmHg) 76.0 ± 7.5 85.1 ± 12.1 <0.001
Urinary albumin (mg/l) 9.0 (4.9–150.1) 14.5 (3.3–150.1) <0.001
Waist circumference (cm) 81.5 ± 12.1 91.1 ± 12.2 <0.001
Body mass index (kg/m2) 24.6 ± 4.9 25.9 ± 5.1 <0.001
Diabetes family history (yes) 26.3 (99) 57.9 (391) <0.001
Hypertension family history (yes) 30.2 (114) 40.7 (275) <0.001
Smoking status (ever) a 3.7 (14) 7.3 (49) 0.02
Formal education (none) 10.9 (41) 35.7 (240) <0.001
Occupation
Public servant 27.4 (103) 6.5 (44)
Trader 25.0 (94) 29.5 (198)
Farmer 3.2 (12) 9.7 (65)
Else 34.6 (130) 17.4 (117)
Unemployed 9.8 (37) 36.9 (248) <0.001
Values are expressed as means ± standard deviation, median (range) or % (n). a, include current and quit smoking.
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(aOR, 1.39; Bonferroni-corrected p = 0.056). Due to the
low MAFs of KCNJ11 and PPARγ (Table 2), the calcula-
tion of risk estimates did not yield meaningful results.
The MAFs of CAPN10 variants did not differ between
diabetic patients and controls. Constructing haplotypes,
the most frequent combination of alleles −43 (A), –19
(3 repeats), and −63 (T) was 112 at 0.53, followed by
111 (0.24), 121 (0.12), 221 (0.10), 222 (0.01), 122 (0.004),
and 211 (0.003). None of these conferred a significant
risk for type 2 diabetes. In contrast, two haplotypes were
nominally associated with reduced odds for type 2 dia-
betes: 211 (aOR, 0.32; 95% CI, 0.03-2.92; p = 0.31) and
221 (aOR, 0.73; 95% CI, 0.48-1.10; p = 0.13) (Table 3).
Genetic variants and diabetic traits
In linear regression models, we investigated whether
TCF7L2 and CAPN10 variants were associated with
phenotypic characteristics among controls without type
2 diabetes, including loge-normalized FPG, waist circum-
ference, BMI, systolic and diastolic blood pressure and
urinary albumin. For TCF7L2 rs7903146, median FPG
(IQR) significantly increased with the number of T
alleles: C/C, 4.4 (4.0-4.7); C/T, 4.5 (4.1-5.0); T/T, 4.7
(4.4-5.4) mmol/L (p = 0.001). This association remained
after adjustment for age, gender, BMI and hypertension
status (p = 0.001). Also, a non-significant tendency forincreased diastolic blood pressure was observed in par-
ticipants carrying both risk alleles: C/C, 76 (70–81); C/T,
76 (71–81); T/T, 81 (75–84) mmol/L (p = 0.1). Body
composition and urinary albumin concentrations were
not influenced by TCF7L2 rs7903146 (all p >0.3). As for
the CAPN10 variants, no associations with phenotypic
characteristics in the control group were observed (data
not shown).Discussion
The importance of genetic variants for type 2 diabetes
established in western populations is far from being
understood for sub-Saharan Africans. Here, we have
investigated the role of three type 2 diabetes candidate
SNPs well-known in other populations (TCF7L2
rs7903146, KCNJ11 rs5219, PPARγ rs1801282) in more
than 1000 Ghanaians. Because of ambiguous findings in
another West African study [13], we also included
CAPN10 variants. More than half of the individuals car-
ried the TCF7L2 (T) allele, which was suggestive to in-
crease the odds for type 2 diabetes by roughly 40%. Also,
in healthy controls, FPG was significantly elevated in
carriers of this allele. Remarkably, the KCNJ11 (G) and
PPARγ (C) alleles were practically absent. The respective
minor alleles of CAPN10 variants were frequent but not
associated with type 2 diabetes.
Table 2 Associations of common variants with type 2 diabetes in urban Ghana
Gene SNP Genotype N Controls Type 2 diabetes OR (9% CI) P aOR (95% CI)a P
TCF7L2 rs7903146 n 1049 375 674
C/C 455 182 (48.5) 273 (40.5) Reference
C/T 488 165 (44.0) 323 (47.9)
T/T 106 28 (7.5) 78 (11.6) 1.34 (1.10–1.63) 0.004 1.39 (1.07–1.81) 0.014
MAF (T) 0.30 0.36
KCNJ11 rs5219 n 1052 377 675
A/A 1051 377 (100) 674 (99.9) Reference
A/G 1 0 (0) 1 (0.1)
G/G 0 0 (0) 0 (0) - -
MAF (G) 0.0 0.0007
PPARγ rs1801282 n 1021 365 656
C/C 1020 365 (100) 655 (99.8) Reference
C/G 1 0 (0) 1 (0.2)
G/G 0 0 (0) 0 (0) - -
MAF (G) 0.0 0.0008
CAPN10 rs3792267 n 1048 375 673
G/G 826 289 (77.1) 537 (79.8) Reference
G/A 209 80 (21.3) 129 (19.2)
A/A 13 6 (1.6) 7 (1.0) 0.85 (0.64–1.12) 0.25 0.70 (0.47–1.03) 0.07
MAF (A) 0.13 0.11
CAPN10 rs3842570 n 1048 374 674
2 repeats/2 repeats 622 225 (60.2) 397 (58.9) Reference
2 repeats/3 repeats 376 128 (34.2) 248 (36.8)
3 repeats/3 repeats 50 21 (5.6) 29 (4.3) 1.00 (0.80–1.24) 0.99 1.12 (0.84–1.49) 0.45
MAF (3 repeats) 0.23 0.23
CAPN10 rs5030952 n 1048 374 674
C/C 219 79 (21.1) 140 (20.8) Reference
C/T 523 182 (48.7) 341 (50.6)
T/T 306 113 (30.2) 193 (28.6) 0.98 (0.81–1.17) 0.79 0.98 (0.76–1.25) 0.84
MAF (T) 0.55 0.54
MAF, minor allele frequency. a, The multivariate odds ratio is adjusted for age, gender, BMI ≥25.0 kg/m2 and hypertension status.
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One study limitation is the comparatively small sample
size that did not allow detecting effects of rare variants,
such as of PPARγ and KCNJ11, and which may also con-
tribute to the possibility of type I statistical errors.
Clearly, larger studies purposely designed for determin-
ing the relevance of specific SNPs on a population-wide
level are required. Also, extensive genetic admixture
within the Ghanaian population may have obscured our
findings. Ancient and recent migration from neigh-
bouring countries and North Africa seems responsible
for a highly variable genetic structure [25]. Even though,
the majority of our participants claimed to be of Akan
ethnicity, and this was equally true for controls and
cases with type 2 diabetes, we cannot exclude admixturefrom other ethnic groups. As a potential drawback,
genotyping in duplicates was not done systematically.
Nevertheless, all genotypes were in Hardy-Weinberg
equilibrium, arguing against major typing errors. Study
participants recruited in hospital may not reflect the
genetic make-up of the average Ghanaian population,
particularly when the ratio of cases and controls is 2:1.
On the other hand, neither improved awareness of type
2 diabetes among patients nor management will influ-
ence predisposition and will therefore not affect associa-
tions of the genetic variants with type 2 diabetes. A
major limitation lies in the unmatched design of our
case–control study. Controls were younger, leaner, and
had less hypertension as well as a higher SES than pa-
tients. Some controls may consequently show increased
Table 3 Associations of CAPN10 haplotypes with type 2 diabetes in urban Ghana
Haplotypea Genotype N Controls Type 2 diabetes OR (95% CI) P aOR (95% CI)b P
111 n 1048 374 674
- - 608 219 (58.6) 389 (57.7) Reference
111 - 376 140 (37.4) 236 (35.0)
111 111 64 15 (4.0) 49 (7.3) 1.12 (0.91–1.38) 0.30 1.00 (0.75–1.34) 0.98
Frequency 0.23 0.25
112 n 1048 374 674
- - 224 82 (21.9) 142 (21.1) Reference
112 - 544 183 (48.9) 361 (53.6)
112 112 280 109 (29.1) 171 (25.4) 0.94 (0.78–1.13) 0.51 0.95 (0.74–1.22) 0.67
Frequency 0.54 0.52
121 n 1048 374 674
- - 823 296 (79.1) 527 (78.2) Reference
121 - 205 72 (19.3) 133 (19.7)
121 121 20 6 (1.6) 14 (2.1) 1.07 (0.81–1.40) 0.64 1.40 (0.99–1.99) 0.06
Frequency 0.11 0.12
122 n 1048 374 674
- - 1039 372 (99.5) 667 (99.0) Reference
122 - 9 2 (0.5) 7 (1.0)
122 122 0 0 (0.0) 0 (0.0) 1.95 (0.40–9.44) 0.41 3.87 (0.61–24.52) 0.15
Frequency 0.01 0.01
221 n 1048 374 674
- - 853 298 (79.7) 555 (82.3) Reference
221 - 186 72 (19.3) 114 (16.9)
221 221 9 4 (1.1) 5 (0.7) 0.84 (0.63–1.14) 0.27 0.73 (0.48–1.10) 0.13
Frequency 0.11 0.09
211 n 1048 374 674
- - 1041 369 (98.7) 672 (99.7) Reference
211 - 7 5 (1.3) 2 (0.3)
211 211 0 0 (0.0) 0 (0.0) 0.22 (0.04–1.14) 0.07 0.32 (0.03–2.92) 0.31
Frequency 0.01 0.001
212 n 1048 374 674
- - 1043 372 (99.5) 671 (99.6) Reference
212 - 5 2 (0.5) 3 (0.4)
212 212 0 0 (0.0) 0 (0.0) 0.83 (0.14–5.00) 0.84 - /
Frequency 0.003 0.002
222 N 1048 374 674
- - 1030 370 (98.9) 660 (97.9) Reference
222 - 18 4 (1.2) 14 (2.1)
222 222 0 0 (0.0) 0 (0.0) 1.96 (0.64–6.00) 0.24 1.20 (0.28–5.04) 0.81
Frequency 0.01 0.01
a, Haplotypes were constructed from genotype data using the software package PHASE version 2.1 [23,24].
b, Adjusted for age, gender, BMI ≥25.0 kg/m2 and hypertension status.
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and/or gain weight. In multivariate analysis, we have
accounted for the differences in age (and gender, obesity,
and hypertension) between cases and controls. Never-
theless, we cannot rule out residual attenuation by an
over-representation of young participants in the control
group. We are aware that the definition of type 2 dia-
betes by single FPG measurement and known medica-
tions is sub-optimal. However, it corresponds to general
practice in resource-poor settings and IDF consensus
[26]. Glycated haemoglobin was not used for the diagno-
sis of type 2 diabetes as the high prevalences of
hemoglobinopathies and haemolytic conditions, such as
malaria, may have complicated the interpretation [27].
The present study provides first-time insight into the
role of common polymorphisms – previously associated
with type 2 diabetes in other populations – among a
comparatively large and presumably non-admixed popu-
lation of SSA. So far, most of the work in African popu-
lations, mainly African Americans, has focused on the
TCF7L2 variant, revealing MAFs of around 0.34 and
ORs for type 2 diabetes of 1.37 [8,9,11]. In Caucasians,
these figures are 0.28-0.32 and 1.44 [8]. Two small
African studies, report MAFs of 0.26-0.48 and diverse
risk estimates (ORs: Nigeria, 1.7; Ghana, 1.0, South
Africa, 1.3) [9,11]. We confirm the high frequency of the
T allele in West-Africa as well as its association with
type 2 diabetes and increased FPG. Indeed, these obser-
vations were independent of BMI status, supporting the
concept of reduced insulin secretion via a deficiency of
the gene product TCF7L2 [4]. Interestingly, previous
studies have revealed that frequencies of the T allele are
lowest in North-America and Europe (with a gradient of
increasing frequency from North to South), moderate in
Asia, and highest in Africa [8,9,28].
Surprisingly, we are the first to investigate the impor-
tance of PPARγ rs1801282 and KCNJ11 rs5219 for type
2 diabetes in West Africa. Almost everybody in the
present study population displayed the risk allele of
PPARγ (C) while the risk allele of KCNJ11 (G) was
almost absent. The protective PPARγ (G) variant has a
global allele frequency of around 0.10, with highest
figures in northern Europeans [29]. In Caucasian and
Asian populations, the G variant commonly protects
against type 2 diabetes (OR Caucasians, 0.9; OR Asians,
0.8) [8,10], particularly in populations with a high lipid
contribution to energy intake [30]. For SSA, associations
with type 2 diabetes are conflicting [8,10].
As for KCNJ11 rs5219, only few studies have examined
the importance of the G allele in blacks: In an African
American population, it was associated with reduced
odds of type 2 diabetes; the frequency was 0.06 [12]. A
recent meta-analysis of eight African American cohort
studies has found an increased risk for type 2 diabetesby 10% [8]; and the G allele was absent in a South
African population of Zulu descent [11]. Findings are in-
consistent in Asian populations, while the variant is a
robust marker for type 2 diabetes in Caucasians [8,31].
The functional role of the SNP remains unclear. It is
known to promote hypoinsulinemia, reduction of body
weight and physical endurance [32]. However, activation
of the gene product depends on several other co-factors
that may outweigh the importance of the SNP [33,34].
The near absence of the G allele in our study population
and its contradictory influence in other regions argue for
alternative variants influencing the population-wide vari-
ation in type 2 diabetes risk in SSA.
CAPN10 polymorphisms are associated with diabetic
status in Mexican Americans (OR, 2.8), Botnian Fins
(OR, 2.5) and Germans (OR, 5.0) [35]. Subsequent stud-
ies, however, could not replicate the strength of associ-
ation in Caucasians [36], and the role in African
populations is unclear [12,13,37]. Here, we replicated the
allele frequencies of the most prominent CAPN10 vari-
ants in West Africans. These were neither associated
with type 2 diabetes nor with diabetic traits in this urban
Ghanaian population. The co-existence of susceptibility
variants and protective haplotypes, previously reported
from Caucasian and Indian populations [36,38], may be
responsible for these findings. Indeed, some CAPN10
haplotypes nominally confer a protection against type 2
diabetes in our study population (ORs, 0.45-0.72). How-
ever, the figures contrast previous findings from two
ethnic groups in Ghana, where the 221 haplotype
showed no association with type 2 diabetes (OR, 0.9)
[13]. Clearly, further investigations are warranted to
understand the role of CAPN10 variants and their inter-
play for the risk of type 2 diabetes in SSA.
Conclusions
In conclusion, the TCF7L2 rs7903146 (T) allele, the
most unequivocal genetic factor influencing type 2
diabetes among Caucasians, is very common among
Ghanaians and associated with type 2 diabetes and FPG.
The degree of association is slightly weaker than the one
in Europe. The protective allele of PPARγ rs1801282
and the risk-conferring allele of KCNJ11 rs5219 are
nearly absent and thus have a debatable relevance for
population-wide variation in type 2 diabetes risk in this
area. CAPN10 polymorphisms in SSA might influence
type 2 diabetes risk only in certain combinations. These
results demonstrate the need for the identification of
ethnicity-specific genetic associations with type 2 dia-
betes in SSA. The present replications of single but
well-established loci from other populations can only
serve as the first step to fine-map the candidate genes
and explore their specific associations with type 2 dia-
betes in this region.
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